Caris Life Sciences, Inc. CAI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.25M | -637.00K | -510.00K | 81.96M | 24.33M |
| Total Depreciation and Amortization | 6.61M | 6.54M | 5.07M | 4.29M | 4.87M |
| Total Amortization of Deferred Charges | 311.00K | 299.00K | 2.62M | 605.00K | 2.46M |
| Total Other Non-Cash Items | 23.16M | 48.65M | 17.41M | 17.02M | 16.68M |
| Change in Net Operating Assets | -67.57M | -26.37M | 8.29M | -59.10M | 14.09M |
| Cash from Operations | -22.25M | 28.48M | 32.88M | 44.78M | 62.43M |
| Capital Expenditure | -17.47M | -22.08M | -10.34M | -5.09M | -7.10M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -100.12M | -- | -- | -- |
| Cash from Investing | -17.47M | -122.19M | -10.34M | -5.09M | -7.10M |
| Total Debt Issued | 0.00 | 393.50M | -- | 0.00 | 0.00 |
| Total Debt Repaid | -43.00K | -406.35M | -40.00K | -39.00K | -23.00K |
| Issuance of Common Stock | 24.39M | 3.68M | 920.00K | 3.86M | 1.15M |
| Repurchase of Common Stock | -10.12M | -26.63M | -56.00K | -424.00K | -16.56M |
| Issuance of Preferred Stock | -- | -- | -- | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -1.11M | -- | 0.00 | -5.67M |
| Cash from Financing | 14.23M | -36.90M | 824.00K | 3.40M | -21.10M |
| Foreign Exchange rate Adjustments | -112.00K | -27.00K | -10.00K | -29.00K | 62.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.59M | -130.65M | 23.35M | 43.06M | 34.30M |